Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingchang Xiaopi Decoction is a traditional Chinese herbal prescription used primarily for the treatment of ulcerative colitis (UC) in China. It is formulated as a multi-herb decoction and has demonstrated efficacy in alleviating symptoms such as diarrhea, abdominal pain, abdominal distension, and purulent stool in patients with mild-to-moderate UC. The mechanism of action appears to involve reduction of inflammatory cytokines (notably IL-6, IL-17, and IL-23), moderation of pathogenic T-helper 17 (Th17) cell activity, and inhibition of STAT3 phosphorylation. These effects collectively contribute to the alleviation of intestinal inflammation associated with UC[1]. The main components have been identified by UHPLC-Q-TOF-MS analysis; however, specific constituent herbs are not detailed in the available summary.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingchang Xiaopi Decoction.